RPRX Repros Therapeutics Inc.

0.99
0  -3%
Previous Close 1.02
Open 1.04
Price To book 4.32
Market Cap 26.43M
Shares 26,679,000
Volume 96,479
Short Ratio 6.43
Av. Daily Volume 137,482

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released November 14, 2016.
Proellex
Uterine fibroids (vaginal treatment)
Phase 2 data released September 2016. Announced December 19, 2016 that a meeting with the FDA has been requested - likely during 1H 2017.
Proellex
Endometriosis
CRL December 1 2015. Phase 2 6-month data released August 2016
Enclomiphene
Secondary hypogonadism
Phase 2b data released November 14, 2016. Noted January 30, 2017 that an end of Phase 2 meeting scheduled with FDA before the end of April, 2017. However, company noted April 10, 2017 that they meeting was in fact a Type C Guidance Meeting rather than an end of Phase 2 Type B meeting. Partial clinical hold remains in place.
Proellex
Uterine fibroids (oral treatment)

SEC Filings

  1. 10-K/A (Amend) - Annual report (Section 13 and 15(d), not S-K Item 405) 17795571
  2. 8-K - Current report 17763659
  3. 8-K - Current report 17760644
  4. 8-K - Current report 17751918
  5. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17728230
  6. 8-K - Current report 17728218
  7. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17605231
  8. 8-K - Current report 17566969
  9. 8-K - Current report 17555516
  10. 8-K - Current report 162058969